
MGI has been a cornerstone investor since our Series B round and provided beyond the financial backing the strategic and business development support, through its teams and in particular with Fuchikami-san, to effectively help us expand our business in Japan. Being visible in Japan today, a country leading the next generation stem cell revolution, is rewarding and a must for Promethera. John Tchelingerian, CEO
肝細胞治療の国際的革新企業が重篤な慢性肝疾患患者への治療法を提供
MGIはPrometheraが製造拡大するにあたり必要な共同研究の機会を探す支援をし、日本の規制機関との調整、また企業との事業開発の好機や同業種の影響者との引き合わせにも積極的に関わる。

生命工学専門